CLLU1 Gene Expression Level As a Prognostic ...

4/23/2014

CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia -- Sevinc et al. 118 (21): 4603 -- ASH Annual …

SEARCH:  

Blood (ASH Annual Meeting Abstracts) 2011 118: Abstract 4603 © 2011 American Society of Hematology

Advanced

Online Publication CLL - Biology and Pathophysiology, excluding Therapy

This Article Services Email this article to a friend

CLLU1 Gene Expression Level As a Prognostic Parameter in Patients with Chronic Lymphocytic Leukemia

Download to citation manager

Citing Articles Citing Articles via Google Scholar

Google Scholar Articles by Sevinc, M.

Mustafa Sevinc, Assistant Doctor*,1 , Articles by Soysal, T. Search for Related Content Ahmet Emre Eskazan, Hematologist*,2 , Aydin Karabulut, Msc*,3 , Suzin Catal Tatonyan, Biologist*,3 , PubMed Emine Gulturk, Hematology Fellow*,2 , Articles by Sevinc, M. Articles by Soysal, T. Ayse Salihoglu, Hematology Fellow*,2 , *,2 Social Bookmarking Seniz Ongoren Aydin, Associate Professor ,                         M. Cem Ar, Associate Professor*,4 , What's this? Zafer Baslar, Professor Doctor*,2 , A. Burhan Ferhanoglu, Professor Doctor2 , Nukhet Tuzuner, Professor Doctor*,5 , Yildiz Aydin, Professor Doctor*,2 , Ugur Ozbek, Professor Doctor*,3 and Teoman Soysal, Professor Doctor*,2

   

   

1 Department of Internal Medicine, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, 2 Department of Internal Medicine, Division of Hematology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey, 3 Institute of Experimental Medicine (DETAE), Genetics Department, Istanbul University, Istanbul, Turkey, 4 Internal Medicine/Hematology, Istanbul Research and Training Hospital, Istanbul, Turkey, 5 Department of Pathology, Division of Hematopathology, Istanbul University Cerrahpasa Medical Faculty, Istanbul, Turkey

Abstract 4603 Background: Chronic lymphocytic leukemia (CLL) is the most frequent leukemia in the Western world with an annual incidence of 5/100,000. The clinical course of the disease is highly variable; while some CLL patients experience a stable clinical course that will never affect their morbidity or mortality, some of them will eventually progress and require chemotherapy. In addition to the traditional prognostic markers (e.g. Rai and Binet staging systems), more recently, mutational status of the variable regions of the immunoglobulin heavy chains (IgVH), chromosomal aberrations, CD38 expression and Zeta-chain-associated protein kinase 70 (ZAP70) expression are used to better determine the prognosis in CLL patients. A novel CLL-specific gene, CLL Up-regulated gene 1 (CLLU1) that uniquely overexpressed in CLL patients, was recently demonstrated. It has been shown that CLLU1 mRNA expression levels in CLL patients predict time to initiation of therapy as well as overall survival (OS), and CLLU1 is highly up-regulated in poor-risk groups. The aim of this study is to investigate the relationship between CLLU1 levels and well known prognostic parameters and, to determine the importance of CLLU1 gene on prognosis and clinical course in our CLL patients. Methods: 116 (46 female, 70 male) CLL patients who consecutively visited our outpatient clinic between May 2009 and March 2010 were enrolled in the study. Median age was 60 years (range, 30–87 years). Blood samples were drawn from the patients for CLLU1 determination, and CLLU1 levels were determined by RTPCR method. CLLU1 expression level was counted both in CLL patients and healthy B cells as the difference between CLLU1 and abl (taken as an house keeping gene) gene. Then, they are transformed as folds which is the ratio between CLLU1 level in CLL patients and that in healthy B cells. Patients with CLLU1 expression exceeding the CLLU1 expression of normal (CD19+) B-cells were taken as positive. Each patient was followed for at least one year for survival data. For the statistical analysis, student’s t-test, Mann-Whitney U test and Pearson correlation were used. p